DLA Piper advised Akoya Biosciences (Akoya), a leading biotechnology company that specializes in the development and commercialization of spatial biology solutions, in its public offering of 8,700,000 shares of common stock at a public offering price of US$5.00 per share for gross proceeds of approximately US$43.5 million, without giving effect to the underwriting discount and commission as well as estimated expenses payable by Akoya.
Akoya has granted the underwriters a 30-day option to purchase up to an additional 1,305,000 shares of its common stock at the public offering price. The offering closed on June 12, 2023.
The DLA Piper team that advised Akoya was led by partner Patrick O’Malley (San Diego) with associates Bianca LaCaille and Rebecca Paley-Williams (both in Seattle).
